“Vaccines Don’t Stop The Virus From Spreading”: TRUE or FALSE?

Many people have heard claims that Covid-19 vaccines are ineffective at reducing the spread of the coronavirus. Now we're learning that the Pfizer COVID-19 vaccine does indeed limit virus transmission.

FOX NEWS – Two new Israeli studies into the efficacy of the Pfizer coronavirus vaccines suggest that the vaccine greatly reduces virus transmission.

Both studies require further confirmation and peer-review, but the results indicate a significant reduction for transmission of both symptomatic and asymptomatic spread.

The newest study, published Friday in British medical journal The Lancet, showed an 85 percent reduction in symptomatic COVID-19 within 15 to 28 days, with an overall reduction of infections – including asymptomatic spread – of 75 percent.

Michal Linial, professor of molecular biology and bioinformatics at Jerusalem’s Hebrew University, said the findings were a big step forward.

“Whether it is 75 or 90 percent reduction doesn’t matter – it is a big drop in transmission,” Linial told Reuters … Click source below to read more. 

What Your Blood Type Reveals About Your Covid Risk

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

- Advertisement -

February 18, 2021

THE LANCET – In December, 2020, the Israeli Government approved the BNT162b2 COVID-19 vaccine and initiated a national immunisation campaign prioritising health-care workers (HCWs), as in other countries.

This campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases by mid-January, 2021.

The Sheba Medical Centre, Israel’s largest hospital with 9647 HCWs, began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-CoV-2 infection, were eligible for vaccination.

Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52·4% before dose two, and 90.5% on days 2–7 after dose two.

- Advertisement -

A recent analysis of BNT162b2 vaccine data estimated vaccine efficacy of 89–91% during days 15–28 after the first dose.

We examined early reductions in SARS-CoV-2 infection and COVID-19 rates in vaccinated HCWs.

To assess vaccine-associated rate reductions we analysed a retrospective cohort of 9109 vaccine-eligible HCWs, comparing vaccinated versus unvaccinated.

Active daily symptom reporting and immediate same-day testing allowed for prompt (<24h) detection and investigation of exposed or symptomatic HCWs.

We defined all HCWs with positive SARS-CoV-2 PCR at Sheba Medical Centre or in the community as cases of SARS-CoV-2 infection.

All SARS-CoV-2-infected HCWs were contacted by infection control staff and requested to respond to a contact tracing questionnaire and a clinical questionnaire specifically regarding COVID-19 symptoms.

Symptomatic HCWs were defined as COVID-19 cases. We used the number of days each HCW was unvaccinated or days after the first dose as follow-up time.

Rate ratios and 95% CIs associated with time after first-dose administration were adjusted for community exposure, using the distribution of probability of a positive contact by means of Poisson regression.

The adjusted estimates were subtracted from 1 to obtain rate reductions.

By Jan 24, 2021, of the 9109 eligible staff, 7214 (79%) had received a first dose and 6037 (66%) had received the second dose. 5505 (91%) fully vaccinated HCWs received the second dose on days 21 or 22 after the first dose. 6818 (95%) HCWs were vaccinated at Sheba Medical Centre.

All employees vaccinated in the community (n=396) were required to report dates of first and second dose to the Human Resources department at Sheba Medical Centre.

Overall, there were 170 SARS-CoV-2 infections among HCWs in the period between Dec 19, 2020, and Jan 24, 2021, of which 99 (58%) HCWs reported symptoms and were designated as COVID-19 cases.

Of the 170 HCWs who became infected, 89 (52%) were unvaccinated, 78 (46%) tested positive after the first dose, and three (2%) tested positive after the second dose.

Among the 125 infections that could be traced, 87 (70%) were community acquired and there were no nosocomial clusters.

Compared with a SARS-CoV-2 infection rate of 7·4 per 10 000 person-days in unvaccinated HCWs, infection rates were 5·5 per 10 000 person-days and 3·0 per 10 000 person-days on days 1–14 and 15-28 after the first dose of the vaccine, respectively.

Adjusted rate reductions of SARS-CoV-2 infections were 30% (95% CI 2–50) and 75% (72–84) for days 1–14 and days 15–28 after the first dose, respectively … Read more. 

- Advertisement -

TRENDING

Tiger Woods – Here’s Why Blood Was Not Tested After Crash | What’s A GV80?

TMZ.com – There are a lot of questions surrounding why cops didn't take a sample of Tiger Woods' blood after his rollover crash ......

Popular Foods Linked To Urinary Tract Infections

Researchers have found evidence that the meat-production chain is a possible major source of the bacteria that causes human urinary tract infections.

What Does Covid-19 Do To Your Brain?

The National Institutes of Health is planning to launch a new database and biobank to collect information from clinicians about neurological problems associated with COVID-19.

‘Home Grown’ Coronavirus Mutation Found In NYC

Viruses mutate all the time. The more people who are infected, and the longer they are infected, the more chance the viruses have to change. A patient's body will be loaded with billions of copies of a virus, and may will be slightly changed, or mutated. Most will come and go. But sometimes a mutation or pattern of mutations takes hold and gets passed along.
- Advertisement -